BioSpace News Archive

According to Nova one advisor, the global Microfluidics market size is evaluated at USD 23.65 billion in 2022 and is expected to hit around USD 72.09 billion by 2030, growing at a CAGR of 12.40% from 2022 to 2030.

According to Nova one advisor, the global Bioinformatics market size is expected to hit around USD 45.9 billion by 2030 from valued at USD 24.7 billion in 2021 and growing at a CAGR of 16.9% from 2022 to 2030.

Kala Pharmaceuticals, Inc. announced that it has entered into a definitive agreement with a life sciences-focused investor for the sale, in a private placement priced at-the-market under Nasdaq rules, of shares of its common stock and Series E Convertible Non-Redeemable Preferred Stock in two tranches for gross proceeds of up to $31 million.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for KPI-012 for the treatment of Persistent Corneal Epithelial Defect (PCED).

DURECT Corporation announced that DURECT’s board of directors determined that the Company will effect a reverse stock split at a ratio of 1-for-10 as of 5:01 p.m. Eastern Time on December 5, 2022.

Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (“CNS”) disorders, today announced that it has postponed its Special Stockholder Meeting (the “Special Meeting”) originally scheduled for November 29, 2022 to allow additional time for stockholder voting proxies (the “Notice”).

Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, is furthering pre-clinical development of its proprietary doggybone DNA vaccine platform, financed by a new grant received from the Bill & Melinda Gates Foundation.

Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces today that the Investigational New Drug (IND) application of ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease (3CLpro) for COVID-19, has been accepted by China National Medical Products Administration (NMPA).

Micron Biomedical, Inc. secures a $14 million Series A financing will support the company’s development of commercial manufacturing, currently underway and establishes a strong partnership between Micron and LTS Lohmann.

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast at the Evercore ISI HealthCONx Conference on Thursday, December 1, 2022 at 4:20 p.m. EST.